Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Peter Horby, Guilherme Pessoa-Amorim, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 302

Showing 1-25 of 302 citing articles:

Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Gilmar Reis, Eduardo Augusto dos Santos Moreira-Silva, Daniela Carla Medeiros Silva, et al.
The Lancet Global Health (2021) Vol. 10, Iss. 1, pp. e42-e51
Open Access | Times Cited: 373
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Severe covid-19 pneumonia: pathogenesis and clinical management
Amy Attaway, Rachel G. Scheraga, Adarsh Bhimraj, et al.
BMJ (2021), pp. n436-n436
Open Access | Times Cited: 366
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Vanessa Piechotta, Khai Li Chai, Sarah J Valk, et al.
Cochrane library (2020)
Open Access | Times Cited: 327
COVID-19: breaking down a global health crisis
Saad I. Mallah, Omar Ghorab, Sabrina Al-Salmi, et al.
Annals of Clinical Microbiology and Antimicrobials (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 305
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Christian Zanza, Tatsiana Romenskaya, A Manetti, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 144-144
Open Access | Times Cited: 240
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
Ryan S. Thwaites, Ashley Sanchez Sevilla Uruchurtu, Matthew K. Siggins, et al.
Science Immunology (2021) Vol. 6, Iss. 57
Open Access | Times Cited: 214
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Vanessa Piechotta, Claire Iannizzi, Khai Li Chai, et al.
Cochrane library (2021) Vol. 2021, Iss. 5
Open Access | Times Cited: 188
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
Oliver J. McElvaney, Gerard F. Curley, Stefan Rose‐John, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 643-654
Open Access | Times Cited: 181
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby, Marion Mafham, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 139
Is IL-6 a key cytokine target for therapy in COVID-19?
Simon A. Jones, Christopher A. Hunter
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 337-339
Open Access | Times Cited: 137
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19
Xavier Mariette, Olivier Hermine, Pierre‐Louis Tharaux, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 9, pp. 1241-1241
Open Access | Times Cited: 132
Clinical features and prognostic factors in Covid-19: A prospective cohort study
Sanne de Bruin, Lieuwe D. J. Bos, Marian A. van Roon, et al.
EBioMedicine (2021) Vol. 67, pp. 103378-103378
Open Access | Times Cited: 115
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
Federico Angriman, Bruno L. Ferreyro, Lisa Burry, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 655-664
Open Access | Times Cited: 105
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D. Goldman, Philip C. Robinson, Thomas S. Uldrick, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002630-e002630
Open Access | Times Cited: 105
The role of IL-6 and IL-6 blockade in COVID-19
Nicola Potere, Alberto Batticciotto, Alessandra Vecchiè, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 6, pp. 601-618
Closed Access | Times Cited: 101
Impact of COVID-19 on Cardiovascular Disease
Ivan Vosko, Andreas Zirlik, Heiko Bugger
Viruses (2023) Vol. 15, Iss. 2, pp. 508-508
Open Access | Times Cited: 63
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?
Gerwyn Morris, Chiara C. Bortolasci, Basant K. Puri, et al.
Cytokine (2021) Vol. 144, pp. 155593-155593
Open Access | Times Cited: 86
Vitamin D deficiency: concern for rheumatoid arthritis and COVID-19?
Sneha Verma, Ved Chaturvedi, N K Ganguly, et al.
Molecular and Cellular Biochemistry (2021) Vol. 476, Iss. 12, pp. 4351-4362
Open Access | Times Cited: 85
Recent advances in management of COVID-19: A review
Soraya Mouffak, Qamar Shubbar, Ekram Saleh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112107-112107
Open Access | Times Cited: 76
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
Thomas M Drake, Cameron J Fairfield, Riinu Pius, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 7, pp. e498-e506
Open Access | Times Cited: 71
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
Timothy Arthur Chandos Snow, Naveed Saleem, Gareth Ambler, et al.
Intensive Care Medicine (2021) Vol. 47, Iss. 6, pp. 641-652
Open Access | Times Cited: 69
Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients
Emma J. Kooistra, Miranda van Berkel, N. Kempen, et al.
Critical Care (2021) Vol. 25, Iss. 1
Open Access | Times Cited: 68
Page 1 - Next Page

Scroll to top